

Workshop | Bringing health-related life science and technology sectors into IMI2

Agenda

26.11.2014 • White Atrium Building • IMI Programme Office
Avenue de la Toison D'Or 56-60 • Brussels • Belgium

09:00 – 09:30 *Registration & networking breakfast*

IMI2 and its Strategic Research Agenda

09:30 – 9:50 **Introducing IMI2**

Michel Goldman, Executive Director, IMI

9:50 – 10:20 **IMI's Scientific Research Agenda (SRA)**

Salah-Dine Chibout, Head Discovery Investigation Safety & TA, Novartis

10:20 – 10:50 *Coffee break*

IMI Strategic Governing Group (SGG) discussion #1

The promise of new technologies for IMI's strategic research areas:
Neurodegeneration, immunology, translational safety, diabetes and metabolic disorders

10:50 – 11:20 **Case studies by IMI Strategic Governing Group (SGG) representatives:**

- **Improving the impact of imaging solutions on drug safety evaluation**
Gunnar Schuetz, Scientist Contrast Media Research, Bayer
SGG Translational Safety
- **Imaging activities within IMIDIA: a case report from IMI1**
Jacob Hecksher-Sørensen, Team Leader, NovoNordisk
Work package leader of the IMI diabetes project IMIDIA
- **Linking clinical neuropsychiatry and quantitative neurobiology**
Hugh Marston, Head of In Vivo Pharmacology, Eli Lilly
Project leader of future IMI project NeuroPsy

11:20 – 12:20 **Discussion**

Moderator: Hugh Lavery, Senior Scientific Project Manager, IMI

12:20 – 13:30 *Lunch break*

IMI SGG discussion #2

Harnessing the potential of data and knowledge management and exploitation:
Innovative practices and exploitation strategies

13:30 – 14:00 **Case studies by IMI Strategic Governing Group (SGG) representatives:**

- **Data and Knowledge Management SGG: Enabling Platforms and the RADAR project - an IMI2 Case Study**
Anthony Rowe, Director, Translational Informatics and External Innovation,
Janssen R&D IT
SGG Data and Knowledge management
Project leader of future IMI project RADAR
- **Improve preclinical and clinical data analysis: now and tomorrow**
Dominique Brees, Executive Director, Novartis Institutes for Biomedical
Research
SGG Translational Safety

14:00 – 15:00

Discussion

Moderator: Hugh Laverty, Senior Scientific Project Manager, IMI

15:00 – 15:20

Coffee break

Different routes to join and partner with IMI

15:20 – 15:40

Presentation by the European Commission

Irene Norstedt, Head of Unit, Personalised and Innovative Medicines,
DG Research & Innovation, European Commission

15:40 – 16:00

Presentation by EFPIA

Magda Chlebus, Director Science Policy, EFPIA

16:00 – 16:30

Questions & Answers

Action points and conclusions

16:30 – 17:00

Concluding remarks